[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Generate Biomedicines Inc (GENB)

Generate Biomedicines Inc (GENB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,889,342
  • Shares Outstanding, K 128,352
  • Annual Sales, $ 31,890 K
  • Annual Income, $ -203,150 K
  • EBIT $ -184 M
  • EBITDA $ -173 M
  • 60-Month Beta N/A
  • Price/Sales 57.75
  • Price/Cash Flow N/A
  • Price/Book 3.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.51
  • Number of Estimates 3
  • High Estimate $-0.47
  • Low Estimate $-0.55
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.49 +14.25%
on 07/28/26
15.16 -5.90%
on 08/05/26
-0.05 (-0.38%)
since 07/10/26
3-Month
11.88 +20.12%
on 06/02/26
18.18 -21.51%
on 06/30/26
-0.10 (-0.70%)
since 05/11/26

Most Recent Stories

More News
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be...

GENB : 14.27 (-3.06%)
Generate Biomedicines: Q2 Earnings Snapshot

Generate Biomedicines: Q2 Earnings Snapshot

GENB : 14.27 (-3.06%)
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Newly Constructed Phase 2 now 100% Leased

GENB : 14.27 (-3.06%)
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

SOMERVILLE, Mass. , May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday,...

GENB : 14.27 (-3.06%)
This AI Biotech Stock Landed a $10.4 Million Nvidia Investment

Nvidia’s backing highlights growing confidence in AI-powered biotech stocks.

NVDA : 217.50 (-0.02%)
GENB : 14.27 (-3.06%)
NVS : 154.61 (-1.39%)
AMGN : 414.30 (-0.70%)
A Deep Dive Into NVIDIA’s Latest Portfolio Moves

NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.

NVDA : 217.50 (-0.02%)
CRWV : 90.32 (+2.42%)
GENB : 14.27 (-3.06%)
INTC : 97.71 (+0.19%)
SNPS : 410.91 (-0.19%)
COHR : 328.57 (+1.05%)
NBIS : 193.23 (+4.95%)
RXRX : 3.35 (+1.82%)
NOK : 9.44 (+3.40%)
LITE : 820.59 (+0.87%)
MRVL : 212.31 (+1.80%)
Generate Biomedicines: Q1 Earnings Snapshot

Generate Biomedicines: Q1 Earnings Snapshot

GENB : 14.27 (-3.06%)
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

SOMERVILLE, Mass. , May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March 31, 2026, and highlighted...

GENB : 14.27 (-3.06%)
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

SOMERVILLE, Mass. , Feb. 26, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (Nasdaq: GENB) ("Generate"), a clinical-stage generative biology company pioneering the AI revolution in biotechnology...

GENB : 14.27 (-3.06%)

Business Summary

Generate Biomedicines Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Generate Biomedicines Inc. is based in SOMERVILLE, Mass.

See More

Key Turning Points

3rd Resistance Point 15.00
2nd Resistance Point 14.82
1st Resistance Point 14.54
Last Price 14.27
1st Support Level 14.08
2nd Support Level 13.90
3rd Support Level 13.62

See More

52-Week High 18.18
Fibonacci 61.8% 15.44
Fibonacci 50% 14.59
Last Price 14.27
Fibonacci 38.2% 13.74
52-Week Low 11.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.